首页> 外文期刊>Transactions of the Royal Society of Tropical Medicine and Hygiene >Therapeutic efficacy of antimalarial drugs along the eastern Indo-Nepal border: a cross-border collaborative study.
【24h】

Therapeutic efficacy of antimalarial drugs along the eastern Indo-Nepal border: a cross-border collaborative study.

机译:印度东部与尼泊尔边境沿线的抗疟药物的疗效:一项跨境合作研究。

获取原文
获取原文并翻译 | 示例
       

摘要

This collaborative cross-border study was performed to determine the therapeutic efficacy of antimalarial drugs used by the National Programmes for falciparum malaria along the eastern Indo-Nepal border where there is unregulated population movement across the border. The study was conducted at sites in Jhapa District, Nepal and Darjeeling District, India. The study was conducted from August 2003 to February 2004, following the WHO 28 day treatment protocol. The efficacy of chloroquine was tested in India among 91 subjects and of sulfadoxine-pyrimethamine in Nepal among 107 subjects with laboratory-confirmed Plasmodium falciparum malaria. Of the 102 subjects who completed the study in Nepal, there were 21 (20.6%) treatment failures comprising 7 (6.9%) early treatment failures (ETF) and 14 (14.7%) late treatment failures (LTF) (5 late clinical failures [LCF] and 9 late parasitological failures [LPF]). Of the 89 subjects who completed the study in India, there were 46 (51.7%) treatment failures comprising 7 (7.9%) ETFs and 39 (43.8%) LTFs (13 LCFs and 26 LPFs). Based on WHO guidelines both countries need to review their drug policy urgently and make appropriate changes, taking into account aspects of cross-border collaboration in the control of drug-resistant malaria.
机译:这项合作的跨境研究是为了确定印度东部-尼泊尔边境沿线的人口不受管制的恶性疟疾国家计划所使用的抗疟药的疗效。这项研究是在尼泊尔贾帕区和印度大吉岭区的地点进行的。该研究是根据WHO的28天治疗方案于2003年8月至2004年2月进行的。在印度的91名受试者中测试了氯喹的功效,而在尼泊尔的107名实验室确诊的恶性疟原虫疟疾受试者中,测试了氯喹的有效性。在尼泊尔完成研究的102位受试者中,有21位(20.6%)治疗失败,包括7位(6.9%)早期治疗失败(ETF)和14位(14.7%)晚期治疗失败(LTF)(5位晚期临床失败[ LCF]和9例后期寄生虫学失败[LPF])。在印度完成研究的89位受试者中,有46位(51.7%)治疗失败,包括7位(7.9%)ETF和39位(43.8%)LTF(13位LCF和26位LPF)。根据世界卫生组织的指导方针,两国都需要紧急审查其药物政策并作出适当的改变,同时考虑到控制耐药性疟疾方面的跨界合作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号